Lopinavir and Ritonavir
In patients infected with 2019-nCoV, clinical trials (e.g., ChiCTR2000029539) were initiated to study HIV protease inhibitors such as Lopinavir and Ritonavir. Lopinavir and Ritonavir were initially suspected to inhibit SARS and MERS 3-chymotrypsin-like protease and seemedto be correlated in a non-randomized open-label trial 2, with improved clinical outcomes of SARS patients. It was revealed that Lopinavir and Ritonavir were associated with significant clinical benefit (less adverse clinical outcomes) among SARS-CoV patients [43]. The combination of Lopinavir and Ritonavir is currently a recommended antivirus regimen approved by the National Health Commission of the People’s Republic of China in the latest form of Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 5) [44].